If you’re looking at treatment options for a certain kind of lung cancer, your doctor might suggest Tabrecta (capmatinib). Learning about the possible side effects can help you know what to ...

If you have a certain kind of lung cancer, your doctor might suggest Tabrecta as a treatment option. It’s a prescription drug used to treat certain kinds of non-small cell lung cancer (NSCLC ...

Novartis has exclusive worldwide development and commercialization rights to Tabrecta The approval of Tabrecta is based on results from the pivotal GEOMETRY mono-1 study. In the METex14 population ...

EAST HANOVER, N.J., May 6, 2020 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) approved Tabrecta ™ (capmatinib, formerly INC280), an oral MET inhibitor ...

Tabrecta (capmatinib) will treat patients with metastatic non-small cell lung cancer that has a mutation leading to MET exon 14 skipping. The drug is the first targeted option for patients with lung ...

Incyte, a global biopharmaceutical company, announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Tabrecta (capmatinib) for MET exon 14 skipping (METex14) ...

“The positive CHMP opinion for Tabrecta brings an option to patients for a treatment specific to their tumor. If approved by the European Commission, new targeted therapies like Tabrecta ...

The agency Wednesday approved Tabrecta (capmatinib) for metastatic non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations, regardless of whether they’ve tried other ...

FDA SAYS TABRECTA APPROVED FOR LUNG CANCER PATIENTS WHOSE TUMORS HAVE MUTATION LEADING TO MET EXON 14 SKIPPING AS DETECTED BY FDA-APPROVED TEST * FDA SAYS TABRECTA TABLETS APPROVED UNDER ...

Novartis may have jumped out ahead of Merck KGaA with targeted lung cancer med Tabrecta, but the German drugmaker has evened the score. The FDA Wednesday cleared its drug Tepmetko in non-small ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Tabrecta TM (capmatinib) for treatment of adult patients with ...

Basel, April 22, 2022 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion and recommended ...